First transdermal oxycodone nears Phase III as Phosphagenics cues up next opioid target
This article was originally published in Scrip
Executive Summary
With formulation issues for its lead therapeutic product now resolved, Phosphagenics looks set to apply for the approval of a pivotal clinical program for its first-in-class transdermal oxycodone product well within the first half of next year.